Bio-Techne (TECH)
Health Care · Life Science Tools and Reagents · NASDAQ
Bio-Techne is a global life science company providing essential reagents, analytical tools, and diagnostic solutions to accelerate biological research and improve disease diagnosis.
What Bio-Techne does
Bio-Techne develops, manufactures, and sells high-quality life science reagents, analytical instruments, and diagnostic products for the research, diagnostics, and bioprocessing industries. The company operates through two primary segments: Protein Sciences, which focuses on biological reagents and proteomic analytical tools, and Diagnostics and Spatial Biology, which provides regulated diagnostic assays, spatial genomic instrumentation, and tissue-based analysis tools. Bio-Techne supports scientific discovery, drug development, and clinical diagnostics with a global portfolio of hundreds of thousands of specialized products.
Themes: proteomics, spatial biology, genomics, drug discovery tools, cell and gene therapy manufacturing, clinical diagnostics
Fundamentals
- Price$72.45 as of 2026-10-08 close
- Market cap$11.4B as of 2026-08-17 (share count; price 2026-10-08)
- 1-year return+19.6% 2025-10-08 close $60.56 → 2026-10-08 close $72.45
- P/E105.00 as of 2026-10-08
- Net margin+6.0% FY2025, SEC XBRL
- Gross margin+65.8% FY2026, SEC XBRL
- ROE+3.8% FY2025, SEC XBRL
- Debt / equity0.10 as of 2026-09-02
- Revenue growth (YoY)+0.2% as of 2026-09-02
- Revenue CAGR (3y)+2.2% SEC XBRL
- Beta1.07 as of 2026-09-02
- Last reported earnings2026-08-12 SEC EDGAR Form 8-K (Item 2.02)
Dividend: yield +0.4%; at least 6 years of non-decreasing per-share dividends (SEC XBRL) — a stock split inside this window left the earlier years on a different per-share basis, so the real streak may be longer.
How TECH compares in its sector
- price-to-earnings ratiotop 10% 185 covered Health Care peers, as of 2026-10-08
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-02
- operating margintop 25% 417 covered Health Care peers, as of 2026-09-02
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-02
- return on equitymiddle range 510 covered Health Care peers, as of 2026-09-02
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- indicated dividend yieldbottom 25% 72 covered Health Care peers, as of 2026-09-02
- free cash flow (absolute dollars, latest fiscal year)top 25% 494 covered Health Care peers, as of FY2026
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
TECH is not currently in any published Top 10 list. Its scores are below.
Top 10 score
52.2 #614 of 1,379 scored · #73 of 151 in Health Care
Financial health 80th (debt to equity 0.1, free cash flow margin 21.7%) and trend 80th (it is at or near its highest point of the past year); weakest is valuation (21st, price to earnings 105, price to book 5.4).
Scores as of 8 Oct 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 4.
Dividend coverage (FY2026)
Covered by reported results. In FY2026, TECH's dividend was covered by reported results (free-cash-flow payout 19%). This describes past coverage, not a forecast.
- Earnings payoutnot assessable earnings not reported
- Free-cash-flow payout19% dividends / (operating cash flow − capex)
Coverage derived from reported SEC EDGAR XBRL figures for FY2026 (dividends paid vs. net income and free cash flow, same fiscal year). This describes PAST coverage for one fiscal year — it does not predict whether a dividend will be maintained, raised, or cut, and a one-year payout ratio can be distorted by non-recurring items. Informational only — not financial advice.
How Bio-Techne looks technically
Bio-Techne (TECH) is trading 16.1% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 53 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 10 trading days ago. It is trading right at its highest price of the past year (its 52-week high).
Trend
7
| Distance from the 200-day | it is trading 16.1% above its 200-day average, the long-term trend line — a longer-term uptrend | +16.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $72.32 | $72.32 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $62.39 | $62.39 |
| Swing structure | its recent peaks and dips disagree — one of them is rising while the other is not, so there is no clean up or down pattern in the swings | mixed — one of the two is not confirming |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 53 trading days ago — a "golden cross", a bullish long-term signal | 53 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with buyers in control | 34.6 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 55, neither overbought (above 70) nor oversold (below 30) | 54.8 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($72.33 to $72.69) — its "stochastic" reading is 33 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. Read that with care: its whole 14-day range is only about 0.5% of the price, so being at one end of it is a smaller move than it sounds — a company pinned near an agreed takeover price does this. | 33.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 60 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $72.69 | $72.69 |
|---|---|---|
| From the 52-week high | it is trading right at its highest price of the past year (its 52-week high) | -0.3% |
| Above the 52-week low | it is 67.7% above its 52-week low (its lowest price of the past year) | +67.7% |
| Below the 52-week high | it is at or near its highest point of the past year | 0.3% |
| Since a 20-day breakout | it made a new 20-day high about 10 trading days ago | 10 sessions |
| Since a 55-day breakout | it made a new 55-day high about 10 trading days ago | 10 sessions |
| All-time high | its highest closing price on record is $135.96 (set on 2021-09-23) | $135.96 |
| Given back of the 52-week move | over the past year its closes ranged ($43.30 to $72.61), and it has given back essentially none of its rise from last year’s low — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $53.56 to $54.50. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 0.6% |
| From the all-time high | it is 46.7% below its all-time high | -46.7% |
| Nearest price level | it is sitting right on a support level at $72.20 — a price it turned at 11 times since 2026-01-22, most recently on 2026-09-30. Since 2024-10-08 it has 10 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -0.3% |
| All-time low | its lowest closing price on record is $11.32 (set on 2006-08-08) | $11.32 |
| Above the all-time low | it is 540.2% above its all-time low | +540.2% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 90% of it) | 10th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.1897 between its high and its low — about 0.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.1897 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $72.21 and $72.67 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $72.21 – $72.44 – $72.67 |
| Typical daily range (% of price) | its price moves about 0.3% in a typical session — among the calmest in the catalog. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 0.3% |
| Stretch from the 200-day average | it is trading 53.0 daily ranges above its 200-day average price (16.1% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale. Read that multiple with care: this company's daily range is unusually small (about 0.3% of its price), which is what makes the multiple large — a stock trading in a narrow band near a takeover price does this | 53.0 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.91× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.3% since the prior reading | -0.3% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Price gaps
1
| Gap at the open | it opened on 2026-10-08 at essentially the same price it closed at the session before — no meaningful overnight gap | +0.0% |
|---|
Price streaks
1
| Closing streak | it closed lower in its latest session, after a session that did not close lower — a single down day rather than a run | 1 session down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 0.8 percentage points (the stock gained 0.2% while the market gained 1.0%) | -0.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 1.7 percentage points (the stock gained 2.1% while the market gained 3.8%) | -1.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 17.2 percentage points (the stock gained 34.7% while the market gained 17.5%) | +17.2% |
| vs market, 12 months | over the past 12 months this stock beat the market by 4.7 percentage points (the stock gained 19.6% while the market gained 15.0%) | +4.7% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a strong uptrend, with buyers in control, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: MACD momentum is negative — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 0.3% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is thick, spanning 11.6% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | +0.3% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 13% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $64.25 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | +12.8% |
|---|---|---|
| Vs the average paid since it last reported | the price is sitting right on the average price paid since it last reported on 2026-08-12 (its 8-K), so the typical buyer over that stretch is roughly break-even. That average is $72.38 — a volume-weighted average of daily closes over 41 sessions, not a true tick-by-tick VWAP. | +0.1% |
Price levels it has turned at before
TECH last closed at $72.45 on 2026-10-08. Since 2024-10-08 it has turned at 10 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $72.20 | Support | 0.3% below the last close | turned there 11 times · 2026-01-22 to 2026-09-30 |
| $70.16 | Support | 3.2% below the last close | turned there four times · 2024-12-19 to 2026-07-08 |
| $78.95 | Resistance | 9.0% above the last close | turned there three times · 2024-12-11 to 2025-02-05 |
| $65.52 | Support | 9.6% below the last close | turned there three times · 2024-11-20 to 2025-11-25 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Near the 52-week high · in a strong, established uptrend (ADX) · beating the market · Least volatile (2% or less typical daily range) · Trading above the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.85 mean, 1=Strong Buy…5=Strong Sell) — 10 analysts
- Mean price target$70.50 range $50.00 – $73.00; median $73.00
Analyst estimates, as of 2026-10-06. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for TECH
- Consensus EPS estimate$0.4491 next reporting period, as of 2026-10-06
- Estimate change, 30 days-$0.07024 (-13.5%) from $0.5193, on 2026-09-01, 35-day window
- Readings revised upward14% of 7 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Reliance on acquisitions to drive growth and expand product portfolios.","Exposure to global market fluctuations and potential integration challenges from international operations.","Significant competition within the life science and diagnostic tool markets."]
What changed in the latest 10-Q
AI-assisted comparison of TECH's 10-Q filed 2026-05-06 against the prior one filed 2026-02-04.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing reports nine months ended March 31, 2026 data (filed 2026-05-06); older filing reports six months ended December 31, 2025 data (filed 2026-02-04)
- Newer filing: consolidated net sales for nine months ended March 31, 2026 were $893.8 million, a decrease of 1%
- Newer filing: consolidated net sales for quarter ended March 31, 2026 decreased 2% to $311.4 million
- Newer filing: consolidated gross margins for quarter ended March 31, 2026 were 66.9% and nine months were 65.7%
- Newer filing: adjusted gross margins for quarter ended March 31, 2026 were 70.4% and nine months were 69.7%
- Newer filing: gross margin table shows nine-month period March 31, 2026 vs. March 31, 2025 comparisons
- Newer filing: selling, general and administrative expenses decreased 28% to $109.3 million for quarter and 13% to $339.2 million for nine months ended March 31, 2026
- Removed:
- Older filing reported quarterly data for quarter ended December 31, 2025 (remained flat at $295.9 million)
- Older filing reported six months ended December 31, 2025 were $582.4 million, a decrease of 1%
- Older filing: consolidated gross margins for quarter and six months ended December 31, 2025 were 64.6% and 65.1%
- Older filing: adjusted gross margins for quarter and six months ended December 31, 2025 were 68.5% and 69.4%
- Older filing: gross margin reconciliation table with December 31, 2025 vs. December 31, 2024 comparisons
- Older filing: selling, general and administrative expenses decreased 6% to $113.7 million for quarter and 4% to $229.9 million for six months ended December 31, 2025
- Reworded:
- Organic revenue performance description changed from 'favorable performance by our Diagnostics and Spatial Biology portfolio offset by unfavorable product mix in our Protein Sciences segment' to 'unfavorable volume and product mix in our Protein Sciences segment, partially offset by favorable performance in our Diagnostics and Spatial Biology portfolio'
- Comparison periods changed from December 31, 2024/2025 to March 31, 2025/2026 throughout financial tables
- Notes:
- The two filings cover different reporting periods (six months vs. nine months) and use different comparison years, making some numerical differences expected rather than substantive operational changes
- MD&A introduction, OVERVIEW section, and segment descriptions are identical between the two filings
Risk Factors
- Added:
- Newer filing reports nine months ended March 31, 2026 compared to nine months ended March 31, 2025 (filed 2026-05-06)
- Newer filing balance sheet dated March 31, 2026 compared to June 30, 2025 (filed 2026-05-06)
- Newer filing cash flows for nine months ended March 31, 2026 compared to nine months ended March 31, 2025 (filed 2026-05-06)
- Removed:
- Older filing reported quarter ended December 31, 2025 compared to December 31, 2024 (filed 2026-02-04)
- Older filing reported six months ended December 31, 2025 compared to December 31, 2024 (filed 2026-02-04)
- Older filing balance sheet dated December 31, 2025 compared to June 30, 2025 (filed 2026-02-04)
- Older filing cash flows for six months ended December 31, 2025 compared to December 31, 2024 (filed 2026-02-04)
- Reworded:
- Period label changed from 'Six Months Ended' to 'Nine Months Ended' in consolidated statements of cash flows
- Period label changed from 'Six months ended December 31, 2025' to 'Nine months ended March 31, 2026' in stockholders' equity statement
- Notes:
- The two filings represent different interim periods within the same fiscal year, making direct financial comparisons not meaningful for assessing actual operational changes
- Text appears truncated at end of stockholders' equity statement in both versions, limiting full comparison of that section
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-04. The 5 days since 2026-10-04 have not been checked yet.
- Last 180 days · read to 2026-10-040 buys · 1 sell ($320386) — 1 selling insider
Most recent open-market transaction: 2026-05-08. Based on Form 4 filings read through 2026-10-04; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about TECH's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
U.S. House trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 14 matched disclosures for TECH from U.S. House Clerk Periodic Transaction Report filings.
U.S. House trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding TECH as of 2026-06-30 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 34,927,956
- Reported value $2,467,660,079
reported quarterly holdings change (2026-03-31 → 2026-06-30): 0 new, 5 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Ask about TECH's institutional holders → See what each manager we track holds →
Short interest (FINRA)
TECH had 6,627,623 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
TECH had 4.23% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.66 days to cover at the same settlement.
- Reported short interest (shares) 6,627,623
- Short interest (% of shares outstanding) 4.23%
- Prior settlement (shares) 5,889,876
- Reported change 12.53%
- Days to cover (reported) 2.66
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Thermo Fisher Scientific (TMO)
- Danaher (DHR)
- Merck KGaA (MRK.DE)
- Revvity
- Agilent Technologies (A)
- 10x Genomics (TXG)
- Illumina (ILMN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare TECH vs…
Bio-Techne is found in…
Frequently asked questions
What does Bio-Techne (TECH) do?
Bio-Techne develops, manufactures, and sells high-quality life science reagents, analytical instruments, and diagnostic products for the research, diagnostics, and bioprocessing industries. The company operates through two primary segments: Protein Sciences, which focuses on biological reagents and proteomic analytical tools, and Diagnostics and Spatial Biology, which provides regulated diagnostic assays, spatial genomic instrumentation, and tissue-based analysis tools.
What sector is Bio-Techne (TECH) in?
Bio-Techne (TECH) is classified in the Health Care sector. Its industry is Life Science Tools and Reagents. It trades on NASDAQ.
Does TECH pay a dividend?
Yes — Bio-Techne (TECH) pays a dividend, with an indicated yield of about 0.44% and at least 6 years of non-decreasing per-share dividends (SEC EDGAR XBRL) — a stock split inside this window left the earlier years on a different per-share basis, so the real streak may be longer (market data, as of 2026-09-02). Informational only — not financial advice.
Who are Bio-Techne's (TECH) competitors?
Notable peers of Bio-Techne (TECH) include Thermo Fisher Scientific, Danaher, Merck KGaA, Revvity and Agilent Technologies. This peer set is informational only — not financial advice.
Has there been recent U.S. House stock trading in TECH?
Yes — we hold 14 matched STOCK Act disclosures for TECH from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Bio-Techne (TECH) overbought or oversold right now?
Bio-Techne (TECH) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 55, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on TECH come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest; prices are market data, as of 2026-09-02; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.